Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Lung Cancer

Journal Scan / Research · February 14, 2022

HRQoL With Adjuvant Osimertinib in Patients With Resected EGFR-Mutated NSCLC

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
Clin. Cancer Res 2022 Jan 10;[EPub Ahead of Print], M Majem, JW Goldman, T John, C Grohe, K Laktionov, SW Kim, T Kato, HV Vu, S Lu, S Li, KY Lee, C Akewanlop, CJ Yu, F de Marinis, L Bonanno, M Domine, FA Shepherd, S Atagi, L Zeng, D Kulkarni, N Medic, M Tsuboi, RS Herbst, YL Wu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading